Evaluation of the safety and immunogenicity of inactivated SARS-CoV-2 Vaccine (Vero Cells) in healthy population aged 18 years and above: a randomized, double-blind, placebo parallel-controlled phase II clinical trial
Latest Information Update: 07 Feb 2023
At a glance
- Drugs COVID-2019 vaccine-Shenzhen Kangtai Biological Products (Primary)
- Indications SARS-CoV-2 acute respiratory disease
- Focus Pharmacodynamics
- Sponsors Beijing Minhai Biotechnology; Shenzhen Kangtai Biological Products
- 28 Apr 2021 Primary endpoint has been met. (neutralization antibody seroconversion and titer), as per Results published in the Chinese Medical Journal
- 28 Apr 2021 Status has been changed to active, no longer recruiting, as per Results published in the Chinese Medical Journal
- 28 Apr 2021 Results from ChiCTR2000038804 and ChiCTR2000039462; assessing preliminary immunogenicity and safety of an inactivated SARS-CoV-2 vaccine, published in the Chinese Medical Journal